lipodystrophy syndrome

lipodystrophy syndrome

AIDS A clinical state characterized by redistribution of fat, increased waist size, and loss of fatty tissue from the face, arms and legs, caused by protease inhibitors used to manage HIV-1-infected Pts Clinical Redistribution of fat Adverse effects N&V, maculopapular rash, headache, fatigue, headache, vertigo. See AIDS, Nonnucleoside reverse transcriptase inhibitor.

lipodystrophy syndrome

A side effect encountered in the treatment of HIV patients with protease inhibitors in which they develop abnormal accumulations of body fat (e.g., over the upper back), hypercholesterolemia, hyperglycemia, hypertriglyceridemia, and insulin resistance.

antiretroviral treatment-related lipodystrophy syndrome

HIV-related fat redistribution syndrome.

facial lipodystrophy syndrome

Facial lipoatrophy syndrome.
References in periodicals archive ?
Patients with HIV who are receiving NRTIs or Pis can present with drug-induced lipodystrophy syndrome, which is associated with hyperglycemia, hyperinsulinemia, hyperlipidemia, and hypertension, and ultimately may cause metabolic syndrome.
Calsolari et al., "Novel mutations of the BSCL2 and AGPAT2 genes in 10 families with Berardinelli-Seip congenital generalized lipodystrophy syndrome," Clinical Endocrinology, vol.
Mutations in FBN1 are also associated with a large spectrum of diseases including Marfan syndrome, Weill-Marchesani syndrome, Stiff skin syndrome, MASS syndrome, and Marfan lipodystrophy syndrome [8-10].
Hamilton et al., "Fat distribution is altered in HIV-infected men without clinical evidence of the HIV lipodystrophy syndrome," HIV Medicine, vol.
PIs cause IR which is also associated with lipodystrophy syndrome. Prolonged therapy with indinavir causes increase in free fatty acid levels which secondarily contribute to IR, may cause redistribution of fat and hypertriglyceridemia.
Lipodystrophy syndrome encompasses three clinical conditions characterized by abnormal body fat distribution; (i) lipoatrophy (peripheral fat wasting), (ii) lipohypertrophy (central fat accumulation), and (iii) mixed lipodystrophy (combination of both lipoatrophy and lipohypertrophy).
HIV-associated lipodystrophy syndrome (HALS) is characterized by morphological changes due to the heterogenous disorders to the fatty tissue, leading to body fat redistribution, associated or not with metabolic alterations.
HIV-associated lipodystrophy syndrome. AIDS 2000; 14 Suppl 3:S197-207.
[USPRwire, Wed Feb 03 2016] GlobalData's clinical trial report, "HIV-Associated Lipodystrophy Syndrome Global Clinical Trials Review, H2, 2015" provides an overview of HIV-Associated Lipodystrophy Syndrome clinical trials scenario.
Central obesity is also one aspect of the lipodystrophy syndrome highlighted as significant in the development of met-syn among HIV+ adults (4).